medical cannabis
medical cannabis · page 6
- Cannabis Daily News
Cannabis News Today — Friday 8 May 2026: Repeal Efforts Collapse as Industry Faces Fresh Legal and Strategic Tests
Repeal campaigns stall in Arizona as Idaho medical cannabis activists oversubscribe their ballot push, fresh research on legalisation arrests lands, and the industry’s medical-marketing claims and Tilray’s expansion playbook draw scrutiny.
- US & Canada
‘Not Immediately Compliant’: What the CRS Says America’s Rescheduling Order Actually Delivers
Since President Trump issued an executive order to expedite cannabis rescheduling in December 2025, questions over the legal implications of this route have hung over the industry.
- Cannabis Daily News
Cannabis News Today — Thursday 7 May 2026: Rescheduling Pressure Builds as White House Sounds Potency Alarm
Today’s cannabis news is dominated by rescheduling momentum, with operators racing to secure DEA Schedule III status even as the White House raises fresh concerns over high-potency products, while the UK, Brazil and Idaho underline how rapidly access is broadening on multiple fronts.
- Medical Cannabis
Curaleaf Laboratories Becomes First UK Manufacturer of Medical Cannabis Suppositories and Pessaries
Curaleaf Laboratories Becomes First UK Manufacturer of Medical Cannabis Suppositories and Pessaries Curaleaf Laboratories today announced a significant milestone in the advancement of medical cannabis treatments in the United Kingdom, becoming the first licensed manufacturer in the country to develop and produce medical cannabis suppositories and pessaries.
- Cannabis Daily News
Cannabis News Today — Tuesday 5 May 2026: DEA Floodgates Open as Industry Races to Register
Cannabis drugmakers prepare for IPOs, nearly 400 operators rush to register with the DEA, microdosing data reframes consumer use patterns, and regulators from Israel to the Bahamas reshape their frameworks as Schedule III aftershocks ripple worldwide.
- CBD Market
The War on Europe’s Legal Hemp Industry
In April 2025, the Italian government used emergency constitutional powers to bypass parliament and reclassify non-intoxicating hemp as a narcotic, regardless of THC content, following multiple failed attempts to decimate the industry.
- Interviews
‘Thoughtful, Prudent, Patient’ – Why Village Farms Is Sitting Out the M&A Rush
The M&A scramble for Europe has continued at a fearsome pace over the last few weeks.
- Industry Trends
DEA’s Schedule III Cannabis Order: A Free-For-All for Telehealth Platforms, or the Perfect Setup for the Entire Industry?
As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling in.
- M&A Activity
Has Rescheduling Accelerated the Cannabis M&A Wave?
Last week’s rescheduling announcement has placed a spotlight firmly on the medical cannabis arms of North America’s largest operators.
- Cultivation
‘More Cannabis Than Colombia’: How Jersey is Reshaping European Supply Chains
The Channel Island of Jersey supplied Germany’s medical cannabis market with more flower than Colombia last year, recent data shows.
- Policy & Regulation
The US Officially Reschedules Cannabis, Partly….
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete step toward rescheduling cannabis.
- Investment & Finance
Federal Agencies Reportedly Told to Prep for Imminent Cannabis Rescheduling Announcement
Cannabis stocks have once again been sent flying in the wake of the latest hint of progress on cannabis rescheduling from Trump’s White House.
